Safe, Innovative and Effective Orthopaedic Therapies

Treatments That Stimulate the Body’s Natural Healing Process

Our treatment alternatives may help keep patients out of the hospital, providing therapies that are easily administered either at the patient’s home or in the doctor’s office.

Faster Fracture Healing with EXOGEN

Patients who are recovering from fractures are increasingly turning to EXOGEN to aid their healing process. EXOGEN is the only FDA approved bone growth stimulator that uses ultrasound waves to activate cells near the site of the break. EXOGEN is particularly useful in healing non-union bone fractures that might otherwise require surgery to heal. EXOGEN only requires 20 minutes a day of use, and has been clinically proven to heal 86% of non-union bone fractures.1 EXOGEN can also speed the healing of an indicated* broken tibia or radius by 38% – this could shorten recovery time by weeks.2, 3

Find out if the EXOGEN Ultrasound Bone Healing System is right for you.

BONES Studies Information

Announced in March of 2017, Bioventus has commissioned an innovative series of clinical studies to further validate the ability of the EXOGEN® Ultrasound Bone Healing System to mitigate the risk of a fracture progressing to nonunion in the presence of known risk factors. Learn more at https://www.bioventusglobal.com/news/bones-overview/

Joint Therapies That Ease Pain and Increase Mobility

When osteoarthritis strikes at joints, it depletes the body’s natural lubrication, which can cause so much pain and discomfort that sometimes the entire joint is replaced surgically. Bioventus offers effective joint therapies that:

– Attacks the pain directly in the joints
– Provides pain relief that can last for months
– Re-lubricates the joints for increased mobility
– Improves cartilage integrity that further reduces joint pain

Discover how our joint therapies are the solution osteoarthritis patients need. Our treatments can be administered right in the physician’s office, taking only 10-15 minutes to administer.

Patients inside the U.S. can learn about GELSYN-3(TM) by visiting www.GELSYN3.com or SUPARTZ FX® by visiting www.SUPARTZFX.com

Patients outside the U.S. can learn about DUROLANE® by visiting www.DUROLANE.com

References

1. Nolte PA, van der Krans A, Patka P, Janssen IM, Ryaby JP, Albers GH. Low-intensity pulsed ultrasound in the treatment of nonunions. J Trauma. 2001;51(4):693-703.

2. Heckman JD, Ryaby JP, McCabe J, Frey JJ, Kilcoyne RF. Acceleration of tibial fracture-healing by non-invasive, low-intensity pulsed ultrasound. J Bone Joint Surg Am. 1994;76(1):26-34.

3. Kristiansen TK, Ryaby JP, McCabe J, Frey JJ, Roe LR. Accelerated healing of distal radial fractures with the use of specific, low-intensity ultrasound. A multicenter, prospective, randomized, double-blind, placebo-controlled study. J Bone Joint Surg Am. 1997;79(7):961-73.

*EXOGEN Summary of Indications for Use: The EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established non-unions† excluding skull and vertebra. In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization.

There are no known contraindications for the EXOGEN device. Safety and effectiveness has not been established for individuals lacking skeletal maturity; pregnant or nursing women; patients with cardiac pacemakers; on fractures due to bone cancer; or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling, at www.exogen.com or by contacting customer service at 1-800-396-4325.

†A non-union is considered to be established when the fracture site shows no visibly progressive signs of healing.

GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g. acetaminophen). Do not administer to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations. Do not inject GELSYN-3 into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site.

GELSYN-3 is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found in product labeling, at www.GELSYN3.com/PIor by contacting customer service at 1-800-836-4080.

SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women or children. Risks can include general knee pain, warmth and redness at the injection site. Full prescribing information can be found in product labeling, at www.SUPARTXFX.com or by contacting customer service at 1-800-396-4325.

DUROLANE indications vary by market, but include the following: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, toes and temporomandibular and facet joints. DUROLANE is also indicated for pain following joint arthroscopy either in the presence of osteoarthritis or subsequent to general surgical repair within 3 months of the procedure.

There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Full prescribing information can be found in product labeling, at www.durolane.com or by contacting customer service at 1-800-396-4325.